| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.01 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |